Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study

Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Puoti M, Rockstroh JK, Klein MB, Dore GJ, Mocroft A, Soriano V, et al. Clin Infect Dis. 2008;47(11):1468-1475.

Publication Type:

Journal Article

Authors:

Tedaldi, E.; Peters, L.; Neuhaus, J.; et, al

Source:

Clin Infect Dis, Volume 47, Issue 11, p.1468-1475 (2008)

Keywords:

administration & dosage, Adult, Anti-Retroviral Agents, Antibodies, Antigens, blood, complications, drug therapy, epidemiology, Female, hepatitis, Hepatitis B, Hepatitis B Surface Antigens, Hepatitis B Virus, Hepatitis C, Hepatitis C Antibodies, HIV Infections, Humans, Incidence, Interruption, Male, Medicine, methods, Middle Aged, Mortality, Patients, Philadelphia, Research, Research Support, Risk, Risk Factors, therapeutic use, therapy

Cited On:

Patients With HIV/HCV Coinfection

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/18959492

Export Citation:

RIS Format

Top